BiomedReports.com
Completion of Cel-Sci's New Facility Signals That Long Awaited Phase III Trial is Imminent
Published in Cancer Weekly, November 10th, 2009
BioMedReports, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, was given an exclusive tour of CEL-SCI Corporation's, (NYSE AMEX:CVM) new, state-of-the-art manufacturing facility near Baltimore, MD where the potentially ground breaking cancer immunotherapy treatment, Multikine, will be manufactured to support an upcoming Phase III clinical trial.
Multikine is the company's flagship immunotherapeutic head and neck cancer treatment and is the first immunotherapeutic agent being developed as a first-line standard of care cancer treatment. Because it required a very...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-11-10)
More Articles from Cancer Weekly
- Breast Cancer
New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors - Cancer Gene Therapy
Data on cancer gene therapy detailed by M. Grohmann and co-authors - Cancer Gene Therapy
New cancer gene therapy research from V. Mlakar and colleagues discussed - Cancer Gene Therapy
New cancer gene therapy study results from University of Texas described - Cancer Vaccines
New findings reported from V.T. Ho and co-authors describe advances in cancer vaccines - Cancer Vaccines
Researchers at University of Washington target cancer vaccines - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
